There is no consensus on the effect of BCL6 translocation on prognosis of DLBCL, especially in the rituximab era, with studies showing either favorable (16, 17), neutral (18, 19), or unfavorable outcomes (20). Here, BCL6 is linked to diffuse large B-cell lymphoma.